帕罗西汀与氟哌噻吨美利曲辛治疗躯体形式障碍对照研究

A contrast study on paroxetine and deanxit in the treatment of somoatoform disorder

目的:探讨帕罗西汀与氟哌噻吨美利曲辛治疗躯体形式障碍的疗效及安全性。方法:将56例躯体形式障碍患者随机分为两组,A组以帕罗西汀治疗,B组以氟哌噻吨美利曲辛治疗,疗程均为8周。治疗前与治疗第1,2,4,8周采用症状自评量表(SCL-90)、汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)评定临床疗效,不良反应量表(TESS)评定不良反应。结果:两组治疗2,4,8周末SCL-90、HAMD、HAMA评分均较治疗前减少(P<0.05或P<0.01);氟哌噻吨美利曲辛较帕罗西汀能更快改善患者的抑郁和焦虑症状(P<0.05)。治疗第8周末A组有效率为82.6%,B组有效率为73.0%(P<0.05)。两组不良反应发生率差异无统计学意义,大多出现在治疗早期,经对症治疗逐渐缓解。结论:帕罗西汀与氟哌噻吨美利曲辛治疗躯体形式障碍均有较显著的疗效,且安全性较高,临床可根据患者自身情况适当选用。

Objective ：To explore the effectiveness and safety of use of paroxetine and deanxit treating somatoform disorders. Methods ：Fifty-six patients with somatoform disorders were randomly divided into A and B of two group, the A group treated by paroxetine and the B group treated by deanxit. The treatment of two group lasted for 8 weeks. In the pre-treatment and treatment of 1,2,4,8 weekend with the somatizatlon factor of Symptom Checklist 90（SCL- 90） ,Hamilton Depression.Rating Scale （HAMD） and Hamilton Anxiety Scale （HAMA） assessment efficacy,side ef- fects scale（TESS） assessment of adverse reaction. Results ：The scores of SCL-90,HAMD and HAMA were decreased significantly in both groups after treatment for 2,4 and 8 weeks （P〈0.05 or P〈0.01）. Deanxit obtained effectiveness more quickly than paroxetine in treating the anxiety and depression of the patients （P〈0.05）. Effect rate of the A group was 82.6% and that of the ]3 group was 73.0% （P〈0.05） after 8 weeks treatment. There were no significant differences for occurring rate of side effects both of the two groups. Most occurred in the initial stage of treatment and gradually remitted via expectant treatment. Conclusion：There were no significant differences in the effectiveness and safety of paroxetine and deanxit in treating somatoform disorders and that＇s appropriate to choose ccording to the patient＇s own clinical conditions.